PEGYLATED GRANULOCYTE COLONY STIMULATING FACTOR (GCSF)
This invention relates to novel PEGx-GCSF conjugates, wherein x is the amount of PEG per GCSF and ranges from 4 to 8. The invention also relates to PEG[x]-GCSF populations of individual PEGx-GCSF conjugates, wherein [x] is the average amount of PEG per GCSF of the population and is 4 or greater. The...
Gespeichert in:
| Hauptverfasser: | , , , |
|---|---|
| Format: | Patent |
| Sprache: | eng ; fre |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | |
| container_title | |
| container_volume | |
| creator | ABUCHOWSKI, Abraham BUONTEMPO, Peter J KAZO, Friedericke JUBIN, Ronald G |
| description | This invention relates to novel PEGx-GCSF conjugates, wherein x is the amount of PEG per GCSF and ranges from 4 to 8. The invention also relates to PEG[x]-GCSF populations of individual PEGx-GCSF conjugates, wherein [x] is the average amount of PEG per GCSF of the population and is 4 or greater. The inventive compositions have unexpected therapeutic efficacy, while avoiding or substantially reducing the likelihood of adverse side effects.
La présente invention concerne de nouveaux conjugués PEGx-GCSF, x étant la quantité de PEG par GCSF et valant de 4 à 8. L'invention concerne également des populations PEG[x]-GCSF de conjugués PEGx-GCSF individuels, [x] étant la quantité moyenne de PEG par GCSF de la population et valant 4 ou plus. Les compositions de l'invention présentent une efficacité thérapeutique inattendue, tout en évitant ou en réduisant sensiblement la probabilité d'effets secondaires indésirables. |
| format | Patent |
| fullrecord | <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_WO2016201448A2</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>WO2016201448A2</sourcerecordid><originalsourceid>FETCH-epo_espacenet_WO2016201448A23</originalsourceid><addsrcrecordid>eNrjZDALcHWP9HEMcXVRcA9y9Av18XeODHFVcPb38feLVAgO8fQNBcp6-rkruDk6h_gHKWi4Owe7afIwsKYl5hSn8kJpbgZlN9cQZw_d1IL8-NTigsTk1LzUkvhwfyMDQzMgNjGxcDQyJk4VAMjQKOs</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>PEGYLATED GRANULOCYTE COLONY STIMULATING FACTOR (GCSF)</title><source>esp@cenet</source><creator>ABUCHOWSKI, Abraham ; BUONTEMPO, Peter J ; KAZO, Friedericke ; JUBIN, Ronald G</creator><creatorcontrib>ABUCHOWSKI, Abraham ; BUONTEMPO, Peter J ; KAZO, Friedericke ; JUBIN, Ronald G</creatorcontrib><description>This invention relates to novel PEGx-GCSF conjugates, wherein x is the amount of PEG per GCSF and ranges from 4 to 8. The invention also relates to PEG[x]-GCSF populations of individual PEGx-GCSF conjugates, wherein [x] is the average amount of PEG per GCSF of the population and is 4 or greater. The inventive compositions have unexpected therapeutic efficacy, while avoiding or substantially reducing the likelihood of adverse side effects.
La présente invention concerne de nouveaux conjugués PEGx-GCSF, x étant la quantité de PEG par GCSF et valant de 4 à 8. L'invention concerne également des populations PEG[x]-GCSF de conjugués PEGx-GCSF individuels, [x] étant la quantité moyenne de PEG par GCSF de la population et valant 4 ou plus. Les compositions de l'invention présentent une efficacité thérapeutique inattendue, tout en évitant ou en réduisant sensiblement la probabilité d'effets secondaires indésirables.</description><language>eng ; fre</language><subject>HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><creationdate>2016</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20161215&DB=EPODOC&CC=WO&NR=2016201448A2$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,776,881,25543,76294</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20161215&DB=EPODOC&CC=WO&NR=2016201448A2$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>ABUCHOWSKI, Abraham</creatorcontrib><creatorcontrib>BUONTEMPO, Peter J</creatorcontrib><creatorcontrib>KAZO, Friedericke</creatorcontrib><creatorcontrib>JUBIN, Ronald G</creatorcontrib><title>PEGYLATED GRANULOCYTE COLONY STIMULATING FACTOR (GCSF)</title><description>This invention relates to novel PEGx-GCSF conjugates, wherein x is the amount of PEG per GCSF and ranges from 4 to 8. The invention also relates to PEG[x]-GCSF populations of individual PEGx-GCSF conjugates, wherein [x] is the average amount of PEG per GCSF of the population and is 4 or greater. The inventive compositions have unexpected therapeutic efficacy, while avoiding or substantially reducing the likelihood of adverse side effects.
La présente invention concerne de nouveaux conjugués PEGx-GCSF, x étant la quantité de PEG par GCSF et valant de 4 à 8. L'invention concerne également des populations PEG[x]-GCSF de conjugués PEGx-GCSF individuels, [x] étant la quantité moyenne de PEG par GCSF de la population et valant 4 ou plus. Les compositions de l'invention présentent une efficacité thérapeutique inattendue, tout en évitant ou en réduisant sensiblement la probabilité d'effets secondaires indésirables.</description><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2016</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZDALcHWP9HEMcXVRcA9y9Av18XeODHFVcPb38feLVAgO8fQNBcp6-rkruDk6h_gHKWi4Owe7afIwsKYl5hSn8kJpbgZlN9cQZw_d1IL8-NTigsTk1LzUkvhwfyMDQzMgNjGxcDQyJk4VAMjQKOs</recordid><startdate>20161215</startdate><enddate>20161215</enddate><creator>ABUCHOWSKI, Abraham</creator><creator>BUONTEMPO, Peter J</creator><creator>KAZO, Friedericke</creator><creator>JUBIN, Ronald G</creator><scope>EVB</scope></search><sort><creationdate>20161215</creationdate><title>PEGYLATED GRANULOCYTE COLONY STIMULATING FACTOR (GCSF)</title><author>ABUCHOWSKI, Abraham ; BUONTEMPO, Peter J ; KAZO, Friedericke ; JUBIN, Ronald G</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_WO2016201448A23</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng ; fre</language><creationdate>2016</creationdate><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><toplevel>online_resources</toplevel><creatorcontrib>ABUCHOWSKI, Abraham</creatorcontrib><creatorcontrib>BUONTEMPO, Peter J</creatorcontrib><creatorcontrib>KAZO, Friedericke</creatorcontrib><creatorcontrib>JUBIN, Ronald G</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>ABUCHOWSKI, Abraham</au><au>BUONTEMPO, Peter J</au><au>KAZO, Friedericke</au><au>JUBIN, Ronald G</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>PEGYLATED GRANULOCYTE COLONY STIMULATING FACTOR (GCSF)</title><date>2016-12-15</date><risdate>2016</risdate><abstract>This invention relates to novel PEGx-GCSF conjugates, wherein x is the amount of PEG per GCSF and ranges from 4 to 8. The invention also relates to PEG[x]-GCSF populations of individual PEGx-GCSF conjugates, wherein [x] is the average amount of PEG per GCSF of the population and is 4 or greater. The inventive compositions have unexpected therapeutic efficacy, while avoiding or substantially reducing the likelihood of adverse side effects.
La présente invention concerne de nouveaux conjugués PEGx-GCSF, x étant la quantité de PEG par GCSF et valant de 4 à 8. L'invention concerne également des populations PEG[x]-GCSF de conjugués PEGx-GCSF individuels, [x] étant la quantité moyenne de PEG par GCSF de la population et valant 4 ou plus. Les compositions de l'invention présentent une efficacité thérapeutique inattendue, tout en évitant ou en réduisant sensiblement la probabilité d'effets secondaires indésirables.</abstract><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | |
| ispartof | |
| issn | |
| language | eng ; fre |
| recordid | cdi_epo_espacenet_WO2016201448A2 |
| source | esp@cenet |
| subjects | HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES |
| title | PEGYLATED GRANULOCYTE COLONY STIMULATING FACTOR (GCSF) |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-21T21%3A00%3A47IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=ABUCHOWSKI,%20Abraham&rft.date=2016-12-15&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EWO2016201448A2%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |